BLRX today
$1.56+$0.05 (+3.31%)close Nov 12, 2026Trend
DailyDowntrend (confirmed)
4 hourStrong Bearish
1 hourStrong Bearish
15 minLeaning Bullish
5 minConsolidating
Daily trend turns up above $2.63
Key levels
Resistance$2.42
Resistance$2.20
Latest news & SEC filings
ProductBioLineRx and Hemispherian share ESMO 2026 findings on GLIX1 plus PARP drugs
All BLRX news →About BioLineRx
BioLineRx is a biopharmaceutical company developing treatments for cancer and uncommon diseases. Its approved medicine, APHEXDA (motixafortide), is given with filgrastim to help move stem cells into the blood for collection and later autologous transplant in multiple myeloma patients. The company is also developing GLIX1, an oral small molecule that targets how tumor cells repair their genetic material, for a type of brain cancer and other solid tumors. It operates in Israel and licenses commercialization rights to partners in various regions.
Based on the company's 20-F filed Mar 23, 2026.
Nasdaq · Healthcare
BioLineRx Ltd. (BLRX)
What Is the Price Target for BLRX?
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Is BLRX a Buy or Sell Right Now?
Thesis
- •Revenue growing -95.9% YoY with STRONG trend — consistent growth.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for BLRX.
Start Free Trial →Is BLRX Overvalued or Undervalued?
Valuation Verdict
N/A
Methods Used
N/A
Fair Value
$N/A
38
Moat Score
NONE
4/9
Piotroski Score
150.9
Altman Z-Score
What Is Smart Money Doing with BLRX?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →BLRX Growth Story
Revenue YoY
-95.9%
3yr Revenue CAGR
N/A%
EPS Growth YoY
100%
FCF Growth YoY
81.6%
Revenue Trend
STRONG
Dark Pool Trades for BLRX
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for BLRX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 18:46:13 | $1.52 | 1,054 | $$2K | SELL |
| 18:20:22 | $1.60 | 1,145 | $$2K | SELL |
| 16:41:25 | $1.62 | 1,000 | $$2K | SELL |
| 15:23:12 | $1.60 | 5,110 | $$8K | SELL |
| 16:58:02 | $1.71 | 1,000 | $$2K | SELL |
5 dark pool trades shown · $$15K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for BioLineRx Ltd. (BLRX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →BLRX — frequently asked questions
What is BLRX stock price today?
BioLineRx Ltd. (BLRX) is at $1.56, up 3.31% (+$0.05) at the Nov 12, 2026 close.
Why is BLRX stock moving today?
Latest BLRX news — Oct 23, 2026: BioLineRx and Hemispherian share ESMO 2026 findings on GLIX1 plus PARP drugs
Did BLRX beat earnings?
BLRX last reported on Aug 31, 2026: EPS -$0.77 vs -$0.15 expected — a miss of 413.3%.
Does BLRX pay a dividend?
BLRX does not currently pay a dividend.
What are BLRX support and resistance levels?
Resistance: $2.20, $2.42, $2.60.
What are insiders doing with BLRX?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on BLRX?
Oct 23, 2026: BioLineRx and Hemispherian share ESMO 2026 findings on GLIX1 plus PARP drugs